Published in Thorax on March 01, 1993
Chronic obstructive pulmonary disease . 7: Management of COPD. Thorax (2003) 1.47
Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Thorax (1998) 0.86
Pharmacological treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2006) 0.82
New therapeutic options in the management of COPD - focus on roflumilast. Int J Chron Obstruct Pulmon Dis (2011) 0.78
What role for theophylline? Thorax (1994) 0.77
Effect of theophylline on exercise capacity in COPD patients treated with combination long-acting bronchodilator therapy: a pilot study. Int J Chron Obstruct Pulmon Dis (2012) 0.75
Twelve-minute walking test for assessing disability in chronic bronchitis. Br Med J (1976) 14.74
A measure of quality of life for clinical trials in chronic lung disease. Thorax (1987) 10.87
The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest (1984) 5.19
Effect of attitudes and beliefs on exercise tolerance in chronic bronchitis. Br Med J (Clin Res Ed) (1983) 2.78
Modelling theophylline response in individual patients with chronic bronchitis. Br J Clin Pharmacol (1981) 2.20
Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax (1991) 2.17
Effect of oral salbutamol and slow-release aminophylline on exercise tolerance in chronic bronchitis. Thorax (1981) 2.06
Effects of theophylline on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Chest (1982) 1.87
Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis (1987) 1.85
Reproducibility of walking test results in chronic obstructive airways disease. Thorax (1988) 1.84
Treatment of chronic obstructive pulmonary disease with orally administered theophylline. A double-blind, controlled study. JAMA (1980) 1.76
Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ (1988) 1.53
A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med (1989) 1.39
How many blows really make an FEV1, FVC, or PEFR? Thorax (1983) 1.38
Plasma theophylline concentrations, six minute walking distances, and breathlessness in patients with chronic airflow obstruction. Br Med J (Clin Res Ed) (1984) 1.36
A self paced treadmill walking test for breathless patients. Thorax (1985) 1.36
Measuring functional status in chronic lung disease: conclusions from a randomized control trial. Respir Med (1989) 1.35
The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis (1985) 1.31
Sustained-release theophylline reduces dyspnea in nonreversible obstructive airway disease. Am Rev Respir Dis (1985) 1.30
The relationship between pulmonary function and dyspnea in obstructive lung disease. Chest (1989) 1.30
OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics. Br J Clin Pharmacol (1982) 1.15
A controlled study of slow-release theophylline and aminophylline in patients with chronic bronchitis. Br J Dis Chest (1982) 1.04
The use of theophylline in 'irreversible' chronic obstructive pulmonary disease. An update. Arch Intern Med (1988) 1.03
Efficacy of inhaled metaproterenol and orally-administered theophylline in patients with chronic airflow obstruction. Chest (1986) 1.02
Accuracy of pulmonary function tests in predicting exercise tolerance in chronic obstructive pulmonary disease. Chest (1984) 1.02
Sustained release oral aminophylline in patients with airflow obstruction. Thorax (1981) 1.01
Induction of suppressor T cells in asthmatic children by theophylline treatment. Clin Allergy (1983) 1.00
Theophylline in the management of airflow obstruction. 1. Much evidence suggests that theophylline is valuable. BMJ (1990) 0.93
Dyspnea and diaphragmatic fatigue in patients with chronic obstructive pulmonary disease. Responses to theophylline. Am Rev Respir Dis (1988) 0.86
Physiologic effects of oral bronchodilators during rest and exercise in chronic obstructive pulmonary disease. Chest (1983) 0.84
Effect of aminophylline on exercise performance in patients with irreversible airway obstruction. Arch Intern Med (1986) 0.83
Theophylline in the management of airflow obstruction. 2. Difficult drugs to use, few clinical indications. BMJ (1990) 0.81
A new adaptable computerized system for the measurement of specific airways conductance. Br J Dis Chest (1986) 0.80
Combination of aminophylline (Phyllocontin Continus tablets) and salbutamol in the management of chronic obstructive airways disease. Br J Clin Pharmacol (1980) 0.77
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res (1999) 3.24
BTS guidelines for the management of pleural infection in children. Thorax (2005) 3.02
Modelling theophylline response in individual patients with chronic bronchitis. Br J Clin Pharmacol (1981) 2.20
Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability. Br J Clin Pharmacol (1978) 1.94
The modelling of drug response. Clin Sci (Lond) (1980) 1.79
Electrocardiographic prediction of coronary artery patency after thrombolytic treatment in acute myocardial infarction: use of the ST segment as a non-invasive marker. Br Heart J (1988) 1.75
X-ray CT metal artifact reduction using wavelets: an application for imaging total hip prostheses. IEEE Trans Med Imaging (2000) 1.68
Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis. Thorax (1998) 1.60
Quantitative analysis of the disopyramide concentration-effect relationship. Br J Clin Pharmacol (1980) 1.58
The drug disc. Warning system for drug interactions. Lancet (1973) 1.56
An assessment of digoxin radio-immunoassay. Scott Med J (1973) 1.55
Population pharmacokinetics. Theory and clinical application. Clin Pharmacokinet (1987) 1.53
Theophylline-salbutamol interaction: bronchodilator response to salbutamol at maximally effective plasma theophylline concentrations. Br J Clin Pharmacol (1981) 1.53
Primary cryotherapy with salvage external beam radiotherapy for locally recurrent prostate cancer. Clin Oncol (R Coll Radiol) (2008) 1.43
A clinically significant interaction between ciprofloxacin and theophylline. Eur J Clin Pharmacol (1987) 1.41
Kinetic and dynamic comparison of piretanide and furosemide. Clin Pharmacol Ther (1978) 1.40
The effect of intravascular transfusion for rhesus haemolytic disease on umbilical artery Doppler flow velocity waveforms. Br J Obstet Gynaecol (1989) 1.38
How many blows really make an FEV1, FVC, or PEFR? Thorax (1983) 1.38
Technical report: quantitative assessment of diaphragmatic movement--a reproducible method using ultrasound. Clin Radiol (1992) 1.30
Acute and chronic effects of the converting enzyme inhibitors enalapril and lisinopril on reflex control of heart rate in normotensive man. J Hypertens (1985) 1.29
Gastro-oesophageal reflux and childhood asthma: the acid test. Thorax (1985) 1.29
Experimental design and efficient parameter estimation in population pharmacokinetics. J Pharmacokinet Biopharm (1990) 1.29
Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire. J Antimicrob Chemother (2002) 1.24
Accuracy of recall of surgical histories: a comparison of postal survey data and general practice records. Community Med (1985) 1.22
A survey of extraction techniques for drugs of abuse in urine. Forensic Sci Int (2001) 1.19
Heaf test results after neonatal BCG. Arch Dis Child (1988) 1.15
OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics. Br J Clin Pharmacol (1982) 1.15
Pharmacokinetics and dose requirements of vancomycin in neonates. Arch Dis Child Fetal Neonatal Ed (1999) 1.15
Effect of Helicobacter pylori on parietal cell sensitivity to pentagastrin in duodenal ulcer subjects. Scand J Gastroenterol (1992) 1.14
Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies. Pharm Res (1995) 1.13
The prediction of individual systolic time interval v heart rate regression equations. Br J Clin Pharmacol (1981) 1.13
Systolic time interval v heart rate regression equations using atropine: reproducibility studies. Br J Clin Pharmacol (1981) 1.12
Comparative pharmacokinetics and pharmacodynamics of cardiac glycosides. Br J Clin Pharmacol (1980) 1.11
Modeling of drug response in individual subjects. J Pharmacokinet Biopharm (1980) 1.11
Phenytoin concentrations in mixed, parotid and submandibular saliva and serum measured by radioimmunoassay. Br J Clin Pharmacol (1977) 1.11
Cost-effectiveness of therapeutic drug monitoring: a systematic review. Ther Drug Monit (2005) 1.09
Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J Pharmacokinet Biopharm (1993) 1.09
Who needs molar units for drugs? Lancet (1987) 1.07
Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet (1992) 1.07
The value of therapeutic drug monitoring to the practising physician--an hypothesis needing sensible application. Br J Clin Pharmacol (1989) 1.06
Estimation of gentamicin clearance and volume of distribution in neonates and young children. Br J Clin Pharmacol (1984) 1.04
Hypercholesterolaemia in treated hypertensives: a controlled trial of intensive dietary advice. J Hypertens Suppl (1989) 1.03
Effect of acute alcohol intoxication on the metabolism and plasma kinetics of chlordiazepoxide. Br J Clin Pharmacol (1979) 1.01
Toxicity of salbutamol and theophylline together. Lancet (1983) 1.00
Measurement of systolic time intervals. Br J Clin Pharmacol (1978) 0.98
Population pharmacokinetics of gentamicin in patients with cancer. Br J Clin Pharmacol (1998) 0.98
Analysis of animal pharmacokinetic data: performance of the one point per animal design. J Pharmacokinet Biopharm (1995) 0.97
Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med (2000) 0.96
Disopyramide pharmacokinetics during recovery from myocardial infarction. Br J Clin Pharmacol (1982) 0.95
Factors affecting drug binding in plasma of elderly patients. Br J Clin Pharmacol (1976) 0.95
Outbreak of rotavirus gastroenteritis among premature infants. Br Med J (Clin Res Ed) (1981) 0.94
Population pharmacokinetics of gentamicin in neonates. Dev Pharmacol Ther (1988) 0.94
Antiarrhythmic drugs. Br Med J (Clin Res Ed) (1983) 0.94
Disopyramide in renal impairment. Lancet (1978) 0.92
Prediction of the antihypertensive response to enalapril. J Hypertens (1990) 0.92
Variability in the pharmacokinetics of epirubicin: a population analysis. Cancer Chemother Pharmacol (1992) 0.91
Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue binding. J Pharmacokinet Biopharm (1989) 0.91
Clinical pharmacokinetics: a comprehensive system for therapeutic drug monitoring and prescribing. Br Med J (Clin Res Ed) (1984) 0.90
The application of HPLC to the determination of some 1,4 benzodiazepines and their metabolites in plasma. Br J Clin Pharmacol (1978) 0.90
Adrenergic control of plasma magnesium in man. Clin Sci (Lond) (1987) 0.89
Quantitation of dose and concentration-effect relationships for fenclofenac in rheumatoid arthritis. Br J Clin Pharmacol (1986) 0.89
The pharmacokinetics of mianserin. Br J Clin Pharmacol (1983) 0.88
Haemodynamic, metabolic, and lymphocyte beta 2-adrenoceptor changes following chronic beta-adrenoceptor antagonism. Eur J Clin Pharmacol (1987) 0.88
The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects. J Pharmacokinet Biopharm (1987) 0.88
The mechanism of salbutamol-induced hypokalaemia. Br J Clin Pharmacol (1987) 0.87
Initial blood pressure as a predictor of the response to antihypertensive therapy. Br J Clin Pharmacol (1988) 0.87
Correction equation for ECG time intervals. Br J Clin Pharmacol (1984) 0.86
Treatment of hypertension with clonidine. Br Med J (1970) 0.86
Population pharmacokinetics of rectal theophylline in neonates. Ther Drug Monit (1991) 0.85
Assessment of a combination of doses of fenoterol and ipratropium suitable for a single metered-dose aerosol. Eur J Clin Pharmacol (1979) 0.85
The influence of theophylline on maximal response to salbutamol in severe chronic obstructive pulmonary disease. Eur J Clin Pharmacol (1982) 0.84
Salbutamol induced hypokalaemia: the effect of theophylline alone and in combination with adrenaline. Br J Clin Pharmacol (1988) 0.84
Idazoxan and brain alpha 2-adrenoceptors in the rabbit. Brain Res (1988) 0.84
Altered pharmacokinetics of cyclosporin in heart-lung transplant recipients with cystic fibrosis. Ther Drug Monit (1990) 0.84
A preliminary, clinical pharmacological assessment of L-659,066, a novel alpha 2-adrenoceptor antagonist. Br J Clin Pharmacol (1992) 0.84
Population pharmacokinetics of lisinopril in hypertensive patients. Gerontology (1987) 0.83
Use of a telephone advice line for oncology patients. Clin Oncol (R Coll Radiol) (2005) 0.83
Effect of naproxen on glucose metabolism and tolbutamide kinetics and dynamics in maturity onset diabetics. Br J Clin Pharmacol (1981) 0.82
Effects of oxprenolol on the airways of normal and bronchitic subjects. Eur J Clin Pharmacol (1976) 0.82
Studies with abanoquil (UK-52,046) a novel quinoline alpha 1-adrenoceptor antagonist: I. Effects on blood pressure, heart rate and pressor responsiveness in normotensive subjects. Br J Clin Pharmacol (1991) 0.82
Pharmacodynamic modeling of the antihypertensive response to amlodipine. Clin Pharmacol Ther (1993) 0.82
Dialysis at home in the west of Scotland: a comparison of hemodialysis and continuous ambulatory peritoneal dialysis in age- and sex-matched controls. Perit Dial Int (1992) 0.82
The pharmacokinetics of R- and S-tocainide in patients with acute ventricular arrhythmias. Br J Clin Pharmacol (1986) 0.82
Interpretation of simulation studies for efficient estimation of population pharmacokinetic parameters. Ann Pharmacother (1993) 0.81
Maximum voluntary cough: an indication of airway function. Bull Eur Physiopathol Respir (1988) 0.81
Hirschsprung's disease associated with a deletion of chromosome 10 (q11.2q21.2): a further link with the neurocristopathies? J Med Genet (1994) 0.81
Disopyramide in acute myocardial infarction: problems with changing pharmacokinetics. Eur J Clin Pharmacol (1986) 0.81
Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis. Eur J Clin Pharmacol (1991) 0.81